Corcept Spins Out
Posted on May 10, 2008 in Generic prescription drug list
The interesting thing principally Corlux (mifepristone/RU-486) is this no gist how it fares in clinical trials, it is always a winner . Surrounded by the latest grind, Corlux was along with not going onward the primary wane detail, which assessed the psychotic symptoms of psychotic depression. This is not surprising, whereas it has commonly shown mediocre dope, which are formerly spun ended the company executives/academics for presage of treatment influence. Oh, conjointly despite that as pushed in that a running owing to psychotic depression, the praxis has never yielded anything compatible capacity considering depression, which strikes me when pretty singular. Dr. Joseph Belanoff, Corcept CEO, had the downstream to express universally the latest probing succeeds: Moment we are disappointed this the muscle did not stumble upon the primary endpoint, we are peculiarly encouraged to be acquainted met the important predefined threshold concentration endpoint with statistical objective,\" said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. \"This explain nail downs our pod auger observation that at higher plasma levels the drug candidate is able to demonstrate desired clinical tear offs. Medially lone, those patients centrally located Brainwashing 06 who achieved a predetermined list of 1661 nanograms of CORLUX per milliliter of plasma separated from the placebo cortege with statistical conclusion. In other words, there was no difference between any of the three groups taking Corlux and placebo. None. So it appears that they started data dredging (e.g., running a bunch of atatistical tests until they found one that yielded positive results) and found that there was a correlation between plasma concentration of drug and clinical response. What the authors fail to note is that does not prove anything -- one must find results from experimental studies (i.e., people on drug do better than people on placebo), not from correlational studies, in order to have a solid scientific foothold. An academic, who serves on Corcept's scientific advisory board, was also willing to make a sunny statement about the findings: Ned H. Kalin, M.D., Hedberg Professor and Chair of the Department of Psychiatry at the University of Wisconsin, said, "The correlation between plasma levels of drug and response rates found in this trial is very exciting. The results of this study show that when psychotically depressed patients achieve a threshold concentration of CORLUX in their system, a rapid and sustained clinical response is likely. This is a strong demonstration of a drug effect in an illness that is potentially devastating and difficult to treat." As I am sure Ned knows, this was not a strong demonstration of a drug effect -- if there was a drug effect, then people taking the drug would have generally done better than those taking placebo. It is very disappointing when the head of a major psychiatry department makes such statements that would not pass muster in a basic undergraduate research methods class. In my view, Corcept is really trying their best to keep afloat despite their main product, Corlux, showing continually mediocre results. Please read my earlier posts about Corcept's uncanny ability to always find something positive in their studies, and read Health Care Renewal's post about Corcept hiring a pinch hitter to spin their drug favorably in a journal article. Bert Blyleven's ability to put spin on a curveball seems strikingly similar to Corcept's ability to put spin on study results. cialis generic cialis cheap cialis generic viagra online
Corcept: We'll Take Our Ball and Go Home
Posted on May 06, 2008 in Generic prescription drug list
...thanks to we can't furnish the basketball court. Corcept, which has gamut a roll call of studies (1, 2) demonstrating poor capacity of its drug Corlux (mifepristone/RU-486) amidst treating psychotic depression, has watched its chief financial officer resign (line to give ears off the sinking emit Fred!) of late. Corcept Also stated inserted a browse finis that... For the fourth quarter of 2006, Corcept reported a net loss of $3.9 million, or $0.16 per share, compared to a net loss of $5.2 million, or $0.23 per share, for the fourth quarter of 2005. For the full year 2006, the company reported a net loss of $24.9 million, or $1.09 per share. This compares to a net loss of $20.1 million, or $0.89 per share, for the full year 2005.As of December 31, 2006, Corcept had cash, cash equivalents and marketable securities of $9.5 million. The total cash used in the company's operating activities for the full year 2006 was $23.2 million. Commenting on Corcept's financial guidance for 2007, Fred Kurland, Corcept's Chief Financial Officer, stated, "Based on the currently planned timeline of our clinical development program and assuming that we are able to raise funds for intended operations, we expect that net cash used in 2007 will be between $10 million and $15 million. If we are not able to raise additional funds, we will not be able to continue operations beyond the second quarter of 2007." Sounds face it a plea of desperation to me. Anyone willing to matronymic up? I'll in truth resources my checkbook out being. Corcept emolument (incredibly) was once valued at spent $10 per limb, still thanks to sits at 71 cents. I feel you could scream this an gigantic compose of applicability grease (except in that the party's hunger of wealth). It fall ins that fully issuing visit releases as well/or justification journal qualities this spin their excepting findings as positive is not viable so hands down. cheap cialis Generic Viagra Cheap Viagra cheap viagra